Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 12/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ATF4 | P18848 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6141018 | 0.95 | ADRB3 (0.42) | ADRB3ADRB1ADRB2LMNACYP3A4 | |
| SCHEMBL7458989 | 0.90 | HRH3 (0.43) | ADRB3ADRB1ADRB2LMNACYP3A4 | |
| SCHEMBL6141010 | 0.86 | ADRB3 (0.40) | ADRB3ADRB1ADRB2LMNA | |
| SCHEMBL5243498 | 0.86 | LMNA (0.48) | ADRB3ADRB1ADRB2LMNA | |
| SCHEMBL5210039 | 0.85 | MEN1 (0.43) | ADRB3ADRB1ADRB2LMNA | |
| SCHEMBL5205600 | 0.85 | ADRB3 (0.50) | ADRB3ADRB1ADRB2LMNACYP3A4 | |
| SCHEMBL5202580 | 0.84 | ADRB3 (0.55) | ADRB3ADRB1ADRB2LMNACYP3A4 | |
| SCHEMBL5202975 | 0.83 | ADRB3 (0.61) | ADRB3ADRB1ADRB2 | |
| SCHEMBL5203687 | 0.83 | ADRB3 (0.47) | ADRB3ADRB1ADRB2LMNACYP3A4 | |
| SCHEMBL7470047 | 0.82 | ADRB3 (0.45) | ADRB3ADRB1ADRB2LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242083-B1 | PHENOXYPROPANOLAMINES, METHOD FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI AVENTIS (FR) | 2007-03-14 | — | — | EP | claimed |
| EP-1242083-B1 | PHENOXYPROPANOLAMINES, METHOD FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI AVENTIS (FR) | 2007-03-14 | — | — | EP | disclosed |
| US-6867220-B2 | Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2005-03-15 | — | — | US | disclosed |
| US-20030040530-A1 | Phenoxypropanolamines, method for producing them and pharmaceutical compositions containning them | SANOFI-AVENTIS (FR) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040530-A1 | Phenoxypropanolamines, method for producing them and pharmaceutical compositions containning them | CNR1, CORO1C, CBR1 | ADRB3 8/4885ADRB1 16/4885ADRB2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.